Bladder cancer

Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Objectif pédagogique: Gain insight into individual follow-up surveillance regimes in patients with high-risk/very high-risk non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).
Spécialité: Urology
Public cible: CME (basic, intermediate), Residents (senior)
Dernière mise à jour: November 2022
Contexte:
  • Patients with NMIBC and MIBC need surveillance following therapy due to the risk of recurrence and progression
  • Surveillance protocols should be tailored to the risk of recurrence and progression, and depend on prior therapeutic interventions

NMIBC risk stratification according to the EAU and AUA guidelines

*Clinical risk factors: age >70; multiple papillary tumours, tumour diameter ≥3 cm

  1. Babjuk M, Burger M, Compérat E, et al. European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Update March 2022. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
  2. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. Update 2020. Available at: https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline